Manfred Gerlach
#153,442
Most Influential Person Now
Manfred Gerlach's AcademicInfluence.com Rankings
Manfred Gerlachbiology Degrees
Biology
#11641
World Rank
#15051
Historical Rank
Neuroscience
#1901
World Rank
#1957
Historical Rank
Download Badge
Biology
Why Is Manfred Gerlach Influential?
(Suggest an Edit or Addition)Manfred Gerlach's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2017) (714)
- Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? (1994) (707)
- Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients (1995) (662)
- Annual report 2015 (2016) (648)
- AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. (2014) (555)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 (2011) (506)
- The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. (2004) (455)
- Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. (2002) (388)
- Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes (2001) (368)
- Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man (2005) (363)
- Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. (1995) (319)
- MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. (1991) (305)
- Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease (2005) (300)
- The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) (242)
- Brain iron pathways and their relevance to Parkinson's disease. (2001) (225)
- Neuroprotective Strategies in Parkinson’s Disease (2003) (221)
- Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum (2003) (199)
- Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour (2001) (187)
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study (2005) (180)
- The Relevance of Iron in the Pathogenesis of Parkinson's Disease (2004) (178)
- Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings (2004) (178)
- [Neurobiology of attention-deficit hyperactivity disorder]. (2008) (169)
- Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. (2010) (167)
- Iron-binding characteristics of neuromelanin of the human substantia nigra. (2003) (167)
- Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder (2006) (156)
- In Vitro Studies of Ferritin Iron Release and Neurotoxicity (1998) (150)
- Pharmacology of selegiline (1996) (148)
- Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample (2009) (145)
- Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline (2001) (130)
- A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice (2010) (129)
- Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease (2001) (124)
- Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins (2000) (115)
- Potential sources of increased iron in the substantia nigra of parkinsonian patients. (2006) (108)
- Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra (1995) (108)
- Absence of Thermal Hyperalgesia in Serotonin Transporter-Deficient Mice (2003) (107)
- Amino acid specificity of glycation and protein–AGE crosslinking reactivities determined with a dipeptide SPOT library (1999) (105)
- Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD (2012) (104)
- In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage (2005) (102)
- Impaired iron homeostasis in Parkinson's disease. (2000) (101)
- A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome (1996) (101)
- Lack of Hypoxia-Inducible Factor-1α Impairs Midbrain Neural Precursor Cells Involving Vascular Endothelial Growth Factor Signaling (2007) (101)
- Influence of neuromelanin on oxidative pathways within the human substantia nigra. (2002) (99)
- The molecular pharmacology of L-deprenyl. (1992) (97)
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level (1996) (96)
- Genes associated with Parkinson syndrome (2008) (95)
- 5-HT2A promoter polymorphism −1438G/A in children and adolescents with obsessive-compulsive disorders (2002) (94)
- The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. (2004) (94)
- Parkinson's disease: a major hypokinetic basal ganglia disorder (1999) (92)
- Multipotent Neural Stem Cells from the Adult Tegmentum with Dopaminergic Potential Develop Essential Properties of Functional Neurons (2006) (92)
- Potential biomarkers in psychiatry: focus on the cholesterol system (2012) (92)
- MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? (2000) (90)
- “Subcellular Proteomics” of Neuromelanin Granules Isolated from the Human Brain* (2005) (87)
- Altered redox state of platelet coenzyme Q10 in Parkinson's disease (2000) (87)
- TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians* (2018) (85)
- Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease (2009) (84)
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2018) (83)
- Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. (1995) (82)
- Microglia activation is related to substantia nigra echogenicity (2010) (82)
- Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? (1998) (80)
- Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs (2001) (79)
- Proteomic research in psychiatry (2011) (75)
- Dopamine receptor agonists in the therapy of Parkinson’s disease (2004) (75)
- Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease? (1991) (71)
- Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics (2011) (70)
- Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells (2006) (69)
- Anti-melanin antibodies are increased in sera in Parkinson's disease (2009) (67)
- Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome (2006) (65)
- The serotonin transporter in Alzheimer's and Parkinson's disease. (2000) (64)
- Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat (2003) (63)
- Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing (1999) (63)
- Brain dopamine and kinematics of graphomotor functions. (2006) (63)
- Improved Odor Sensitivity in Attention-Deficit/Hyperactivity Disorder (2008) (63)
- A systematic review on olfaction in child and adolescent psychiatric disorders (2012) (61)
- Dolichol is the major lipid component of human substantia nigra neuromelanin (2005) (61)
- Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. (1996) (59)
- Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. (2007) (58)
- Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. (2010) (56)
- Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin? (2002) (55)
- Human Stiff-Person Syndrome IgG Induces Anxious Behavior in Rats (2011) (54)
- Decreased anxiety in mice lacking the organic cation transporter 3 (2009) (54)
- Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial (2010) (54)
- Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. (2007) (53)
- The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants (2005) (53)
- Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder (2014) (53)
- Therapeutic Monitoring of Psychotropic Drugs: An Outline of the AGNP-TDM Expert Group Consensus Guideline (2004) (52)
- Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry (2010) (51)
- The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. (2003) (50)
- Identification of L-ferritin in Neuromelanin Granules of the Human Substantia Nigra (2009) (50)
- Transmission disequilibrium studies in children and adolescents with obsessive-compulsive disorders pertaining to polymorphisms of genes of the serotonergic pathway (2004) (49)
- Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study (2005) (49)
- Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. (2007) (48)
- Oxytocin plasma concentrations in children and adolescents with autism spectrum disorder: correlation with autistic symptomatology (2014) (48)
- Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals. (2007) (47)
- Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. (2008) (47)
- Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia. (1995) (46)
- Evidence for specific phases in the development of human neuromelanin (2006) (46)
- Oxidative stress in the brain at early preclinical stages of mouse scrapie (2006) (45)
- The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery (2011) (45)
- Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients (2005) (45)
- Transmission disequilibrium studies in early onset of obsessive–compulsive disorder for polymorphisms in genes of the dopaminergic system (2008) (44)
- Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. (1995) (44)
- Does Methylphenidate Cause a Cytogenetic Effect in Children with Attention Deficit Hyperactivity Disorder? (2007) (44)
- Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. (2007) (43)
- Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells (2004) (43)
- Parkinson’s Disease and Related Disorders (2006) (43)
- Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy (2009) (42)
- CLINICAL STUDY: Cortisol concentrations, stress‐coping styles after withdrawal and long‐term abstinence in alcohol dependence (2006) (41)
- Iron in the Parkinsonian substantia nigra. (1997) (40)
- Therapeutic Drug Monitoring in Child and Adolescent Psychiatry (2011) (40)
- Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis. (2013) (40)
- Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle (2006) (39)
- Neuromelanin is an immune stimulator for dendritic cells in vitro (2011) (37)
- Interaction of attention and graphomotor functions in children with attention deficit hyperactivity disorder. (2007) (37)
- Altered Frontal and Temporal Brain Function during Olfactory Stimulation in Adult Attention-Deficit/Hyperactivity Disorder (2010) (37)
- Perception in attention deficit hyperactivity disorder (2018) (37)
- Effects of methylphenidate on olfaction and frontal and temporal brain oxygenation in children with ADHD. (2011) (36)
- Neurorestoration in Parkinson’s disease by cell replacement and endogenous regeneration (2004) (36)
- A pilot proteomic study of protein markers in autism spectrum disorder (2014) (36)
- Evidence for specific phases in the development of human neuromelanin (2006) (35)
- Chronic alcohol consumption and cerebral indices of oxidative stress: is there a link? (2001) (35)
- Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain (2001) (35)
- Nitric oxide in the pathogenesis of Parkinson's disease. (1999) (35)
- Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. (2007) (35)
- GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra (2004) (34)
- Increased mRNA levels of the mitochondrial complex I 75-kDa subunit (2006) (34)
- Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection (2016) (34)
- Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy (2011) (34)
- 1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats (1998) (33)
- Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies (2000) (32)
- Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms (2017) (32)
- Effects of secretin on extracellular amino acid concentrations in rat hippocampus (2004) (32)
- Neuromelanin selectively induces apoptosis in dopaminergic SH‐SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component (2008) (31)
- Influence of a genetic variant of the neuronal growth associated protein Stathmin 1 on cognitive and affective control processes: An event‐related potential study (2011) (31)
- The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration (2003) (31)
- Considerations for measuring iron in post-mortem tissue of Parkinson’s disease patients (2012) (31)
- Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity (2014) (31)
- Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements (2008) (31)
- Coenzyme Q10 serum levels in Huntington's disease. (2004) (30)
- Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells (2005) (30)
- Effects of methylphenidate: the cellular point of view (2010) (30)
- Neurotransmitters and Disorders of the Basal Ganglia (1999) (29)
- Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. (1997) (29)
- Involvement of microglia in cerebrospinal fluid glutamate increase in SIV-infected rhesus monkeys (Macaca mulatta). (1999) (29)
- Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat (2007) (29)
- Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. (2008) (28)
- Reduced thermal hyperalgesia and enhanced peripheral nerve injury after hind paw inflammation in mice lacking the serotonin‐transporter (2008) (28)
- Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity (2006) (28)
- Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder (2011) (28)
- Quantitation of 5HT3 receptors in forebrain of serotonin transporter deficient mice (2004) (28)
- MPTP-Induced Parkinsonian Syndrome (1999) (27)
- Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia (2010) (27)
- Allelic variants of SNAP25 in a family-based sample of ADHD (2008) (26)
- Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. (2007) (26)
- Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. (1998) (26)
- Case report: intoxication with high dose of long-acting methylphenidate (Concerta®) in a suicidal 14-year-old girl (2010) (25)
- Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: Preliminary observations (1991) (25)
- Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry (2016) (25)
- Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes (2006) (25)
- Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin (1996) (25)
- No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study (2010) (25)
- Therapeutic Drug Monitoring of Children and Adolescents Treated with Fluoxetine (2011) (24)
- Expression, but not activity, of neuronal nitric oxide synthase is regionally increased in the alcoholic brain. (2001) (24)
- Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. (2010) (23)
- Olfaction in child and adolescent anorexia nervosa (2012) (23)
- Strategies for the protection of dopaminergic neurons against neurotoxicity (2009) (22)
- New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. (1996) (22)
- No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. (2009) (22)
- Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease (2011) (22)
- N-methyl-(R)-salsolinol and its relevance to Parkinson's disease (1998) (21)
- The Relation Between Dosage, Serum Concentrations, and Clinical Outcome in Children and Adolescents Treated With Sertraline: A Naturalistic Study (2013) (20)
- Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. (2001) (20)
- Is selegiline neuroprotective in Parkinson's disease? (1994) (20)
- Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice (2016) (20)
- The Pathophysiological Basis of Parkinson’s Disease (1993) (20)
- Is there neuroprotection in Parkinson syndrome? (2000) (20)
- Levodopa in the treatment of Parkinson's disease: Current controversies (2005) (19)
- LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum (2008) (19)
- Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. (2003) (19)
- Controlled study on the combined effect of alcohol and tobacco smoking on testosterone in alcohol-dependent men. (2006) (19)
- Pharmacotherapy in depressed children and adolescents (2011) (19)
- Psychiatric Drugs in Children and Adolescents (2014) (19)
- [Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations]. (2006) (19)
- Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry (2006) (19)
- What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder? (2017) (19)
- 5-hydroxyindolacetic acid (5-HIAA), a main metabolite of serotonin, is responsible for complete Freund's adjuvant-induced thermal hyperalgesia in mice (2011) (19)
- Itches and scratches – is there a link between eczema, ADHD, sleep disruption and food hypersensitivity? (2011) (18)
- Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat (2004) (18)
- Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate (2007) (18)
- Early Detection of Parkinson’s Disease: Unmet Needs (2008) (17)
- Determination of L-DOPA and 3-O-methyl DOPA in human plasma by extraction using C18 cartridges followed by high-performance liquid chromatographic analysis with electrochemical detection (1986) (17)
- Does the treatment of maternal attention deficit and hyperactivity disorder (ADHD) enhance the efficacy of a behavioural parent training for the treatment of their children’s ADHD? Study protocol of a randomized controlled multicentre trail (2009) (16)
- Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD. (2016) (16)
- Neural degeneration in Parkinson's disease. (2001) (16)
- Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? (2013) (16)
- Formation of Radicals (2004) (16)
- Tolcapone and neurotoxicity in Parkinson's disease (1998) (15)
- Intraoperative microdialysis and tissue-pO2 measurement in human glioma. (1998) (15)
- Mechanisms underlying and medical management of l-Dopa-associated motor complications (2011) (15)
- Glia Protects Neurons against Extracellular Human Neuromelanin (2007) (15)
- Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP (2019) (14)
- [Pharmacovigilance in child and adolescent psychiatry]. (2015) (14)
- Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. (1996) (14)
- Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. (2010) (14)
- Norepinephrine is a negative regulator of the adult periventricular neural stem cell niche (2020) (14)
- No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease in nine ADHD candidate SNPs (2017) (13)
- Neuropsychiatric Disorders: An Integrative Approach (2008) (13)
- Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice. (1993) (12)
- Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. (1999) (12)
- The interactions of 1-alkyl-4,4-diphenylpiperidines with opiate receptors. (1983) (12)
- The Role of Iron in the Pathogenesis of Parkinson's Disease (2006) (11)
- Olfactory deficits in deletion syndrome 22q11.2 (2011) (11)
- Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells (2009) (11)
- The relevance of preclinical studies for the treatment of Parkinson's disease (2003) (11)
- Pathogenesis and pathophysiology of attention-deficit/hyperactivity disorder: from childhood to adulthood (2007) (11)
- No cross-sectional and longitudinal association of ferritin and symptoms of attention-deficit-/hyperactivity disorder in a large population-based sample of children: results from the GINIplus and LISAplus studies (2013) (11)
- New developments in diagnosis and treatment of Parkinson’s disease—From basic science to clinical applications (2004) (11)
- The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson’s disease: differential role of α2 adrenergic mechanisms (2012) (10)
- Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review (2020) (10)
- Biochemical Anatomy of the Basal Ganglia and Associated Neural Systems (1999) (10)
- Transcranial sonography in psychiatry as a potential tool in diagnosis and research (2018) (10)
- No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample (2011) (10)
- Genotoxicity of the neurotransmitter dopamine in vitro. (2009) (10)
- Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson’s Disease (2020) (10)
- Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride (2020) (10)
- Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders (2017) (10)
- Increased hippocampal DNA oxidation in serotonin transporter deficient mice (2002) (10)
- Check and Double Check - the Cochrane review by Storebo et al. (2015) is indeed flawed. (2016) (9)
- Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease (2011) (9)
- Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice (2017) (8)
- Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats (2011) (8)
- Regional distribution and characterization of nitric oxide synthase activity in the brain of the common marmoset. (1995) (8)
- Basic science in Parkinson’s disease: its impact on clinical practice (2011) (8)
- The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats (2009) (8)
- [Drug therapy in child and adolescent psychiatry in Germany between ethical as well as social and legal conflicts]. (2016) (8)
- Psychiatric, nonmotor aspects of Parkinson's disease. (2012) (8)
- A novel technique for the isolation of Lewy bodies in brain (1998) (8)
- The Mode of Action of MAO-B Inhibitors (1993) (8)
- Investigation of the lipid component of neuromelanin (2006) (8)
- Regional distribution and characterization of nitric oxide synthase activity in the brain of the common marmoset (1995) (7)
- (−)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity (1991) (7)
- Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood (2012) (7)
- Special Features of Psychopharmacological Therapy in Children and Adolescents (2014) (7)
- Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD? (2007) (7)
- Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice (2022) (7)
- Brain Iron and other Trace Metals in Neurodegenerative Diseases (2000) (6)
- Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease (2008) (6)
- Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents. (2020) (6)
- A critical review of evidence for preclinical differences between rasagiline and selegiline (2012) (6)
- Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents (2020) (6)
- Postnatal brain development and psychotropic drugs. Effects on animals and animal models of depression and attention-deficit/hyperactivity disorder. (2010) (6)
- Dose-related concentrations of neuro-/psychoactive drugs expected in blood of children and adolescents. (2020) (6)
- Pharmacokinetic investigations of various levodopa formulations (1989) (6)
- Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care (2020) (5)
- Relationship Between Amphetamine Concentrations in Saliva and Serum in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. (2020) (5)
- 4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor biding sites and synaptosomal monoamine uptake. (1988) (5)
- Antioxidative properties of aspirin: dose dependence and clinical implications (1996) (5)
- Biological Role of Neuromelanin in the Human Brain and Its Importance in Parkinson's Disease (2011) (5)
- Psychostimulants and Other Drugs Used in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (2014) (5)
- Spiked human substantia nigra proteome data set for use as a spectral library for protein modelling and protein mapping (2019) (5)
- Family-based association study on functional α-synuclein polymorphisms in attention-deficit/hyperactivity disorder (2019) (5)
- Effects of Selegiline in a retroviral rat model for neurodegenerative disease. (1999) (4)
- Editorial [Hot topic: Psychotropic Drugs in Child and Adolescent Psychiatry - a New Era on the Horizon (Executive Editors: Aribert Rothenberger, Manfred Gerlach and Ralf W. Dittmann)] (2010) (4)
- Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic (2010) (4)
- Laboratory assessments in the course of Parkinson’s disease: a clinician’s perspective (2015) (4)
- Iron, Neuromelanin, and α-Synuclein in Neuropathogenesis of Parkinson's Disease (2003) (4)
- Altered urinary tetrahydroisoquinoline derivatives in patients with Tourette syndrome: reflection of dopaminergic hyperactivity? (2020) (4)
- Pigmentation in the human brain and risk of Parkinson's disease (2010) (4)
- Long-term cardiovascular safety of psychostimulants in children with attention deficit hyperactivity disorder (2019) (4)
- Potential Biomarkers of Parkinson's Disease (2007) (4)
- The effect of silyl substituted methotrexate in the treatment of experimental allergic encephalomyelitis in rats mediated by T-line cells (1987) (4)
- The industrial chemical Tinuvin 123 does not induce dopaminergic neurotoxicity in C57Bl/6 mice (2000) (4)
- Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes (2022) (3)
- Catecholaminergic Innervation of Periventricular Neurogenic Regions of the Developing Mouse Brain (2020) (3)
- Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules. (2021) (3)
- Genomic aspects of sporadic Parkinson's disease. (2008) (3)
- [Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (3)
- Non-Fatal Intoxication with a High Dose of Citalopram in a Suicidal 14-Year-Old Girl. (2019) (3)
- Sustained-release of levodopa: single dose study of a new formulation (2005) (3)
- [Therapy with lithium salts in child and adolescent psychiatry--clinical efficacy and practical recommendations]. (2006) (3)
- Pharmacokinetic studies with sustained-release formulations of levodopa in healthy volunteers. (1988) (3)
- Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro (2002) (3)
- A highly sensitive method for the determination of protein bound 3,4-dihydroxyphenylalanine as a marker for post-translational protein hydroxylation in human tissues ex vivo (2001) (3)
- Neuromelanin may Mediate Neurotoxicity via its Interaction with Redox Active Iron (2000) (3)
- Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. (2022) (3)
- Responsivity of the Striatal Dopamine System to Methylphenidate—A Within-Subject I-123-β-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (2022) (2)
- The Role of Altered Glutathione Status in the Development of Parkinson’s Disease (2018) (2)
- Amyotrophic Lateral Sclerosis—Parkinsonism—Dementia of Guam (1999) (2)
- Hepatolenticular Degeneration: Wilson's Disease (1999) (2)
- Psychotropic drugs in child and adolescent psychiatry--a new era at the horizon. (2010) (2)
- Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old Age (2020) (2)
- Iron Deficiency and Excess in the Brain: Implications for Cognitive Impairment and Neurodegeneration (2009) (2)
- [Current preclinical findings on substances against Parkinson's disease]. (2003) (2)
- Iron-Induced Dopaminergic Cell Death In Vivo as a Model of Parkinson’s Disease (2021) (2)
- Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring (2022) (2)
- Anxiolytics and Sedative-Hypnotics (2014) (2)
- The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies (2022) (2)
- Monoamin-Oxidase-Hemmer (2002) (2)
- [Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases]. (1995) (2)
- [Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants]. (1996) (2)
- Longitudinal impacts of a multimodal intervention program addressed to ADHD children and their parents on children's social skills and behavior problems (2009) (1)
- Special edition on the occasion of Jan K. Buitelaar’s 65th anniversary (2019) (1)
- P.1.c.044 Efficacy and mechanism of antidyskinetic activity of sarizotan (2006) (1)
- MAO-B-Hemmer (1992) (1)
- Consequences of a single short lasting cerebral oligemia and the influence of iron injected into the substantia nigra or in the ventrolateral striatum of the rat. Trigger of Parkinson’s disease pathogenesis? (2004) (1)
- ["Therapeutic drug monitoring", a strategy for improving drug safety in child and adolescent psychiatry and psychotherapy]. (2005) (1)
- [Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice]. (2021) (1)
- Influence of saliva pH-value on the ratio of amphetamine saliva to serum concentration (2018) (1)
- [The Pharmacological Management of Emergencies in Child and Adolescent Psychiatry]. (2021) (1)
- Editors must be vigilant to guarantee the quality and credibility of published scientific work (2018) (1)
- Relation between dosage, serum concentration and therapeutic response of risperidone in children and adolescents with schizophrenic psychosis: data from a routine TDM-Service (2014) (1)
- Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases (2023) (1)
- Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines--implications for the CNS. (2006) (1)
- Therapeutic Drug Monitoring of Quetiapine in Child and Adolescents (2005) (1)
- 4th World Congress on ADHD From Childhood to Adult Disease 06–09 June 2013 · Milan · Italy Editors: Manfred Gerlach, Würzburg, GermanyPeter Riederer, Würzburg, GermanyAndreas Warnke, Würzburg, Germany (2013) (1)
- Peer-reviewed reports on all topics relevant to attention-deficit/hyperactivity disorder (2009) (1)
- Drug- Or Toxin-Induced Movement Disorders (1999) (1)
- Role of iron in 6-hydroxydopamine neurotoxicity. (1999) (1)
- Uniform pattern of immunohistochemical localization of serotonin 5-HT2 receptors in human aortic, mitral, pulmonary and tricuspid heart valves: Implication for the pathomechanism of valvular heart disease following treatment with dopamine agonists (2012) (1)
- Presentation of the AGNP-TDM expert group consensus guideline on „Therapeutic Monitoring of Psychotropic Drugs“ (2004) (1)
- beta-Amyloid deposition and prion infection in adult primary brain cell long-term culture model. (2007) (1)
- A sensitive procedure for the determination of protein bound 3,4-dihydroxyphenyl-alanine as a marker for posttranslational protein hydroxylation in human frontal cortex, liver, and red blood cells. (2001) (1)
- Fundamentals of Neuropsychopharmacology (2014) (1)
- Should the maximum daily doses of levodopa be limited to 400 mg/die? (2014) (1)
- Isolation, Expansion und In-vitro-Charakterisierung adulter mesenzephaler neuraler Stammzellen (2005) (1)
- [Polypharmacy of psychotropic drugs in child and adolescent psychiatry in Germany - rather the rule than the exception]. (2019) (1)
- Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy (2022) (1)
- Therapeutic Drug Monitoring in Children and Adolescents Treated with Second-Generation Antipsychotics in Daily Clinical Practice (2016) (1)
- SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF SILYLATED DOPAMINES AND 4,4-DIPHENYLPIPERIDINES (1983) (1)
- Drug- or Substance-Related Disorders (2014) (1)
- P2.111 Anti-dyskinetic effects of flibanserin on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease (2009) (1)
- Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry (2022) (0)
- Serious adverse drug reactions to antipsychotics in children and adolescents with multiple disabilities: Avoidability and potential cost savings by therapeutic drug monitoring (2022) (0)
- 1.304 Hyperactivity and attention deficit precede the development of Parkinson's disease symptoms (2007) (0)
- IntraoperativeMicrodialysisandTissue-pOzMeasurementin HumanGlioma (1998) (0)
- Therapeutic Drug Monitoring in Children and Adolescent Psychiatry – First Results for Atypical Antipsychotic Drugs (2008) (0)
- Comprar Neuropsychiatric Disorders · An Integrative Approach | Gerlach, Manfred | 9783211735732 | Springer (2007) (0)
- Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD (2009) (0)
- Foreword: Parkinson's Disease: Progress in Neurodegenerative and Clinical Research (2000) (0)
- The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder (2007) (0)
- P.4.026 Increased oxidative stress in alcohol dependent patients as estimated by the in vivo acetylsalicylic acid assay (ASAA) (1996) (0)
- Procedure for determining the neurologically relevant properties of a material (1999) (0)
- Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease (2022) (0)
- S21 NEUROMELANIN AND ITS INTERACTION WITH IRON AS A POTENTIAL RISK FACTOR FOR DOPAMINERGIC NEURODEGENERATION UNDERLYING PARKINSON??S DISEASE (2006) (0)
- Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Short Communication (2021) (0)
- SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF 4,4-DIPHENYL-4-SILA-PIPERIDINES (1982) (0)
- DIADEM / Participants Directory (2004) (0)
- P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice (2009) (0)
- [Drug monitoring and regulatory aspects of psychotropic drugs in childhood and adolescence]. (2009) (0)
- Neurobiology of Neuro-Psychiatric Diseases (2008) (0)
- News from substantia nigra neuromelanin (2005) (0)
- [Mercaptopurine and silylated mercaptopurine the treatment of experimental allergic encephalomyelitis]. (1990) (0)
- Role of neuromelanin as an autoantigen in Parkinson's disease (2013) (0)
- University of Groningen Perception in attention deficit hyperactivity disorder (2017) (0)
- Preface – Special Issue: Neuromelanin (2006) (0)
- Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride (2021) (0)
- Figure 45-1, [The direct pathway contains two...]. (1999) (0)
- Pharmacovigilance in children and adolescents with psychiatric disorders (2014) (0)
- Aripiprazole induced extrapyramidal symptoms in two adolescents (2014) (0)
- Improved Reproducibility of Protein Detection in Neuromelanin-containing Human Substantia Nigra Tissue enriched by Laser Microdissection (2020) (0)
- [Psychopharmacological treatment and youth welfare]. (2009) (0)
- Neurodegenerative diseases as well as psychiatric disorders. (2013) (0)
- 3.119 STRIATAL LONG-TERM DEPRESSION AND DOPAMINE SIGNALING IMPAIRMENT IN A53T-ALPHA-SYNUCLEIN OVEREXPRESSING MICE (2012) (0)
- Letter to the editor (1997) (0)
- [Basic research]. (2009) (0)
- Functional effects of neuromelanin and synthetic melanins in model systems (2005) (0)
- Contents of Volumes in the Metal Ions in Life Sciences Series (2019) (0)
- Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
- Therapeutic drug monitoring (TDM) in children and adolescents during sertraline therapy (2011) (0)
- S.08.01 Potential biomarkers and genetic findings in ADHD (2012) (0)
- Ferritin is located within neuromelanin granules, an iron storing organelle in dopaminergic neurons of the human brain (2007) (0)
- Relation between dosage, serum concentration and therapeutic response of quetiapine in children and adolescents with different psychiatric disorders in clinical practice (2012) (0)
- Interdisciplinary approaches for the understanding of neuropsychiatric disorders (2002) (0)
- Knowledge and beliefs of workers in school, health and social service environments in Quebec (Canada) regarding ADHD (2009) (0)
- GIRK2 – A novel candidate gene for attention deficit hyperactivity disorder (2007) (0)
- Pro-and Antioxidative Properties of Cortical Tissue Preparations from Human Brain Exhibiting NMDA-Receptor Characteristics (1999) (0)
- single dose study of a new formulation (1996) (0)
- Responsivity of the striatal dopamine system to methylphenidate - a within-subject I-123-β-CIT-SPECT study in children and adolescents with Attention-Deficit/Hyperactivity Disorder (2021) (0)
- Methylphenidate effects on cell growth and maturation in neuronal stem cells (2007) (0)
- Therapeutic drug monitoring (TDM) in children and adolescents treated with aripiprazole (2012) (0)
- P.7.d.015 Therapeutic drug monitoring (TDM) of fluoxetine in children and adolescents (2013) (0)
- Unaltered susceptibility to scrapie in serotonin transporter deficient mice (2006) (0)
- [Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (0)
- Electrophysiological properties of neural stem cell-derived midbrain neurons reveal functional dopaminergic differentiation as prerequisite for therapeutic approaches (2007) (0)
- [The impact of attention deficit/hyperactivity disorder (ADHD) in mothers on the treatment of their ADHD children--review and summary of the study protocol of a randomized controlled multi-centre trial on parent training]. (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Manfred Gerlach?
Manfred Gerlach is affiliated with the following schools:
